Western blot analysis of A-431 cells treated with pervanadate (1 mM) for 30 min. Blots were probed with NFKBIA (phospho Y42) polyclonal antibody (Cat # PAB7922). The latter antibodies were used in the presence of no blocking peptide (lane 1), phospho-NFKBIA (Tyr-42) peptide (lane 2), phospho-NFKBIA (Tyr-305) peptide (lane 3), or BSA conjugated to phospho-tyrosine (lane 4). Peptides and BSA-pTyr were used at 1 mg/ml.
NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA (MIM 164014), or RELB (MIM 604758) to form the NFKB complex. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA or NFKBIB, MIM 604495), which inactivate NF-kappa-B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664, or IKBKB, MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G purine; and Y is a C or T pyrimidine).[supplied by OMIM
IkappaBalpha,nuclear factor of kappa light chain gene enhancer in B-cells